<code id='E75D77805B'></code><style id='E75D77805B'></style>
    • <acronym id='E75D77805B'></acronym>
      <center id='E75D77805B'><center id='E75D77805B'><tfoot id='E75D77805B'></tfoot></center><abbr id='E75D77805B'><dir id='E75D77805B'><tfoot id='E75D77805B'></tfoot><noframes id='E75D77805B'>

    • <optgroup id='E75D77805B'><strike id='E75D77805B'><sup id='E75D77805B'></sup></strike><code id='E75D77805B'></code></optgroup>
        1. <b id='E75D77805B'><label id='E75D77805B'><select id='E75D77805B'><dt id='E75D77805B'><span id='E75D77805B'></span></dt></select></label></b><u id='E75D77805B'></u>
          <i id='E75D77805B'><strike id='E75D77805B'><tt id='E75D77805B'><pre id='E75D77805B'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:fashion    Page View:13
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In